SCHEMBL28021626

SCHEMBL28021626

CCC(=O)Nc1ccc(S(=O)(=O)c2nc(CO)cc(Nc3cc(C)n[nH]3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.46
▸ AURKB Q96GD4 13/20 0.43
▸ AURKA O14965 10/20 0.43
▸ ALDH1A1 P00352 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ APBA1 Q02410 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ BCR P11274 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28021678 0.86 ATM (0.45) ATMAURKBAURKAALDH1A1CA12
SCHEMBL28021591 0.85 AURKB (0.51) ATMAURKBAURKAALDH1A1MEN1
SCHEMBL2201749 0.82 AURKB (0.64) AURKBAURKASRCGSK3BABL1
SCHEMBL28021603 0.81 ALDH1A1 (0.42) ATMAURKBAURKAALDH1A1CA12
SCHEMBL28021607 0.77 SLC2A1 (0.44) ALDH1A1MEN1MAPTKMT2A
SCHEMBL28022078 0.76 PKM (0.44) AURKBAURKAALDH1A1CA1CA2
SCHEMBL28565368 0.76 AURKB (0.44) AURKBAURKAALDH1A1CA12CA1
SCHEMBL28022116 0.76 ADORA1 (0.47) AURKBAURKAALDH1A1MEN1MAPT
SCHEMBL28570313 0.76 KMT2A (0.37) AURKAALDH1A1MEN1MAPTKMT2A
SCHEMBL27577294 0.75 AURKB (0.40) AURKBAURKAMEN1KMT2ASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback